2.02
price up icon0.99%   0.0199
after-market Handel nachbörslich: 2.00 -0.02 -0.99%
loading
Schlusskurs vom Vortag:
$2.0001
Offen:
$2.03
24-Stunden-Volumen:
7,224
Relative Volume:
0.70
Marktkapitalisierung:
$23.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-3.15M
KGV:
-6.6186
EPS:
-0.3052
Netto-Cashflow:
$-2.23M
1W Leistung:
-0.98%
1M Leistung:
-11.40%
6M Leistung:
-20.78%
1J Leistung:
-6.05%
1-Tages-Spanne:
Value
$2.00
$2.085
1-Wochen-Bereich:
Value
$1.96
$2.26
52-Wochen-Spanne:
Value
$1.20
$4.0499

Cytomed Therapeutics Ltd Stock (GDTC) Company Profile

Name
Firmenname
Cytomed Therapeutics Ltd
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
34
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
GDTC's Discussions on Twitter

Vergleichen Sie GDTC mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
GDTC
Cytomed Therapeutics Ltd
2.02 23.54M 0 -3.15M -2.23M -0.3052
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Cytomed Therapeutics Ltd Aktie (GDTC) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives CytoMed Therapeutics Limited stock priceExplosive market performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

How high can CytoMed Therapeutics Limited stock price go in 2025Daily Swing Candidates - Newser

Jul 22, 2025
pulisher
Jul 21, 2025

What drives SDST stock priceConsistently profitable trades - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

The ANGELICA Trial and the Future of Allogeneic CAR-T: A Strategic Investment Perspective - AInvest

Jul 21, 2025
pulisher
Jul 21, 2025

CytoMed's Breakthrough Cancer Cell Therapy Shows Promise in Phase 1 Trial, Advances to Higher Dose Testing - Stock Titan

Jul 21, 2025
pulisher
Jul 21, 2025

GDTC advances CTM-N2D: Dose Level 1 complete, Phase I escalates | GDTC SEC FilingForm 6-K - Stock Titan

Jul 21, 2025
pulisher
Jul 19, 2025

COST Stock Analysis and ForecastFree Investment Community - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Is CytoMed Therapeutics Limited a good long term investmentExceptional profit margins - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 19, 2025

Blue Chip Stocks High Precision Stock TipsBreakthrough stock performance - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

CytoMed Therapeutics Limited Stock Analysis and ForecastAccelerated earnings growth - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 18, 2025

What analysts say about CytoMed Therapeutics Limited stockExceptional profit velocity - jammulinksnews.com

Jul 18, 2025
pulisher
Jul 15, 2025

How CytoMed Therapeutics Limited stock performs during market volatilitySmart Money Trade Setups - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes CytoMed Therapeutics Limited stock price move sharplySafe and Scalable Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why CytoMed Therapeutics Limited stock attracts strong analyst attentionTrade With Low Risk Exposure - Newser

Jul 15, 2025
pulisher
Jul 03, 2025

CytoMed Therapeutics shareholders approve all proposals at annual meeting By Investing.com - Investing.com Nigeria

Jul 03, 2025
pulisher
Jul 03, 2025

CytoMed Therapeutics shareholders approve all proposals at annual meeting - Investing.com

Jul 03, 2025
pulisher
Jun 19, 2025

The Pipeline for of iPSC-Derived Cell Therapeutics in 2025 - BioInformant

Jun 19, 2025
pulisher
Jun 14, 2025

Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shel - GuruFocus

Jun 14, 2025
pulisher
Jun 13, 2025

CytoMed Therapeutics Files $50 Million Mixed Shelf - MarketScreener

Jun 13, 2025
pulisher
Jun 13, 2025

Cytomed Therapeutics (GDTC) Files for $50M Mixed Securities Shelf Offering | GDTC Stock News - GuruFocus

Jun 13, 2025
pulisher
May 16, 2025

CytoMed Therapeutics schedules annual shareholder meeting - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

CytoMed Therapeutics schedules annual shareholder meeting By Investing.com - Investing.com India

May 16, 2025
pulisher
May 14, 2025

CytoMed Therapeutics (NASDAQ:GDTC) Stock Price Down 0.4% – Here’s Why - Defense World

May 14, 2025
pulisher
Apr 30, 2025

CytoMed Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

Interview with the Chairman: CytoMed Therapeutics Ltd. (NASDAQ:GDTC) - The Wall Street Transcript

Apr 30, 2025
pulisher
Apr 28, 2025

CytoMed Therapeutics Reports Full Year Ended December 31, - GlobeNewswire

Apr 28, 2025
pulisher
Apr 28, 2025

CytoMed 2024 Results: 39% Lower Losses as Biotech Advances Novel Cancer Cell Therapy Trial - Stock Titan

Apr 28, 2025
pulisher
Apr 28, 2025

BRIEF-CytoMed Therapeutics To Start Dose Level 2 In Angelica Trial Q3 2025 - Yahoo.co

Apr 28, 2025
pulisher
Mar 13, 2025

Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight - The Globe and Mail

Mar 13, 2025
pulisher
Mar 04, 2025

Microbiome Disease Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 140+ Companies and 180+ Therapies | DelveInsight - GlobeNewswire

Mar 04, 2025
pulisher
Feb 27, 2025

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 06, 2025

CytoMed Therapeutics announces Chairman’s Letter to the Company’s shareholders - Marketscreener.com

Feb 06, 2025
pulisher
Jan 09, 2025

SunAct Cancer Institute and CytoMed begin phase 2 trials for Gamma Delta T-cell therapy - Express Healthcare

Jan 09, 2025
pulisher
Jan 07, 2025

SunAct Cancer Institute ties up with Singapore’s CytoMed for phase 2 clinical trials on innovative Gamma Delta T-cell cancer therapy in India - Pharmabiz.com

Jan 07, 2025
pulisher
Jan 06, 2025

CytoMed Partners with SunAct for Groundbreaking Cancer Cell Therapy Trial in India - Stock Titan

Jan 06, 2025
pulisher
Jan 03, 2025

CytoMed Therapeutics Leads 3 US Penny Stocks To Consider - simplywall.st

Jan 03, 2025
pulisher
Dec 05, 2024

CytoMed Therapeutics And 2 Other US Penny Stocks To Watch - Yahoo Finance

Dec 05, 2024
pulisher
Nov 20, 2024

Update on Clinical MilestoneCytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies - Yahoo Finance

Nov 20, 2024
pulisher
Oct 23, 2024

Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap - Yahoo Finance

Oct 23, 2024
pulisher
Oct 17, 2024

Osteopore partners with NASDAQ-listed CytoMed to advance MSC-powered regeneration - Biotech Dispatch

Oct 17, 2024
pulisher
Oct 07, 2024

CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant - GlobeNewswire

Oct 07, 2024
pulisher
Oct 03, 2024

CytoMed Therapeutics completes cash acquisition of Cord - GlobeNewswire

Oct 03, 2024
pulisher
Sep 30, 2024

CytoMed Therapeutics Reports Six Months Ended June 30, 2024 - GlobeNewswire

Sep 30, 2024
pulisher
Aug 16, 2024

iPSC Applications in Cell Therapy, Drug Discovery, and Beyond - BioInformant

Aug 16, 2024
pulisher
Jul 17, 2024

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewswire

Jul 17, 2024
pulisher
Mar 20, 2024

Navigating the Challenges Facing an Aging Global Population: How CytoMed Seeks to Help Boost Cartilage Regeneration | Value Investing NewsInvestor powered stock market news - Financial Content

Mar 20, 2024
pulisher
Mar 04, 2024

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewswire

Mar 04, 2024
pulisher
Jan 23, 2024

GDTC Stock Price and Chart — NASDAQ:GDTC - TradingView

Jan 23, 2024
pulisher
Dec 05, 2023

Singapore-China collaboration to explore allogeneic gamma delta T cell technology for cancer treatment - BioSpectrum Asia

Dec 05, 2023
pulisher
Nov 17, 2023

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PR Newswire

Nov 17, 2023
pulisher
Aug 29, 2023

CytoMed Expands Research Collaboration into China After Entering Into MOU - StreetInsider

Aug 29, 2023

Finanzdaten der Cytomed Therapeutics Ltd-Aktie (GDTC)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):